RT期刊文章SR电子T1日常生活和生活质量改善活动措施Hoehn & Yahr子组先进的帕金森症患者治疗后IPX066,延长释放carbidopa-levodopa乔(P4.008)摩根富林明神经病学神经病学FD Lippincott Williams &威尔金斯SP P4.008 VO 88是16补充A1罗希特迪豪A1雷蒙吉尔提出琳德姆德尔A1伊丽莎白A1资格成为罗伯特•鲁本斯A1 Suneel Gupta年2017 UL //www.ez-admanager.com/content/88/16_Supp首页lement/P4.008.abstract AB目的:描述延长释放的影响carbidopa-levodopa (ER CD-LD)日常生活活动(ADL)和子组的生活质量先进的PD患者基于Hoehn & Yahr(浩英)阶段。背景:ER CD-LD (IPX066 RYTARY®)是一种口服,CD-LD胶囊配方。初始峰值大约一个小时后,等离子体左旋多巴浓度维持大约4 - 5小时。设计/方法:ADVANCE-PD检查的有效性和安全性ER与速释(IR) CD-LD先进的PD患者。病人(n = 393)接受13周的双盲治疗与ER或红外CD-LD。基线的变化统一帕金森病评定量表(UPDRS)第二部分(ADL)分数和39-item帕金森病问卷(PDQ-39)检查治疗每个浩英阶段(i II和iii iv)小组在这事后分析。结果:在整个研究中,UPDRS ADL (P < . 01)和PDQ-39总分(P < . 05)与ER和红外显著提高。ER也产生一个数值更大,但非重大的改进从基线与红外的UPDRS ADL量表浩英i ii(意思是(SD): ER和−0.5−1.7(3.7)(3.4)对IR)和浩英iii iv (ER和+ 0.2−0.9(4.1)(4.5)红外)子组。虽然PDQ-39总分提高数值,之间没有统计上的显著差异治疗组对浩英i ii (−2.6 (12.7) ER和对IR) + 0.1(9.7)或浩英iii iv (ER和−4.4−5.3(11.4)(11.5)红外)子群。浩英iii iv组,PDQ-39迁移成绩更好了ER和红外(P < .04点);这种改善浩英i ii组没有统计学意义。结论:与红外相比,治疗ER CD-LD倾向于产生更大的改善UPDRS ADL和PDQ-39规模浩英i ii和浩英iii iv子组。Study Supported by: Impax Laboratories, Inc.Disclosure: Dr. Dhall has received personal Impax, Merz, Teva, Acadia, Medtronic, UCB, and IO Therapeutics as a speaker and/or consultant. Dr. Gil has received personal compensation for activities with Impax Laboratories, Inc., as a participant in their speaker's bureau. Dr. Gil has been an investigator in clinical trials sponsored by Impax Laboratories, Inc. Dr. Lindemulder has received personal compensation for activities with Impax Laboratories Inc. as an employee. Dr. Rubens has received personal compensation for activities with Impax Laboratories, Inc., as an employee. Dr. Gupta has received personal compensation for activities with Impax Laboratories as an employee.